Go Pro
→ Warren Buffett's Parting Gift is About to Pay Off (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.06
-1.9%		$1.03
$0.84
▼
$12.23
$17.86M-1.72286,127 shs62,265 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+5.88%+24.00%-29.41%-89.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.06
-1.9%		$1.03
$0.84
▼
$12.23
$17.86M-1.72286,127 shs62,265 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+5.88%+24.00%-29.41%-89.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest TPST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest TPST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2016.54 million10.55 millionNo Data

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
July 15, 2026  |  quiverquant.comQ
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html
Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  quiverquant.comQ
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307117/0/en/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors.html
Tempest Therapeutics Announces Resignation of Board Director
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-resignation-of-board-director?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants
May 29, 2026  |  quiverquant.comQ
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303540/0/en/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds.html
Tempest Therapeutics Announces Multiple Board Director Resignations
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-multiple-board-director-resignations?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505685-tempest-therapeutics-tempest-reports-first-quarter-2026-financial-results-and-provides-business-update-399.htm
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295395/0/en/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update.html
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288654/0/en/tempest-presents-clinical-update-at-isct-2026-annual-meeting.html
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283678/0/en/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting.html
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t.html
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273302/0/en/tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts.html
New Strong Buy Stocks for April 10th
April 10, 2026  |  zacks.comhttps://www.zacks.com/commentary/2897019/new-strong-buy-stocks-for-april-10th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$1.06 -0.02 (-1.85%)
As of 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas